Soft Tissue Sarcoma Adult Clinical Trial
Official title:
Sarcomas and DDR-Inhibition; a Neoadjuvant Phase I Combined Modality Study.
To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering DDRi and RT concurrently treating newly diagnosed, non-metastatic soft tissue sarcoma patients with DDRi-based CMT, in the specific context of systemic toxicities, wound healing post-surgery and in defining the RP2D for the combinations to support further clinical evaluation.
Despite improvements in surgery and radiation for soft tissue sarcoma (STS) patients, local relapses remain an important event for these patients. Most STS subtypes are considered radioresistant. Investigations into radiosensitization mediated by combining systemic compounds with neoadjuvant radiotherapy (RT) may translate into an increased rate of pathological responses, an increased rate of R0 resections and thus fewer local relapses. RT is highly potent in inducing DNA damage. Normal cells are usually sufficiently able to repair this damage timely before the next fraction because of an intact DNA Damage Response (DDR) pathway. Frequently, tumor cells have (partial or complete) defects in the DDR pathways rendering them more sensitive to radiation than normal tissues. Inhibition of constituents of the DDR pathways may further widen the therapeutic window of fractionated RT. Clinical studies into radiosensitization of STS by combinations of RT and DDR inhibitors are warranted. In this study the candidate inhibitors is the new drugs AZD1390, targeting ATM (Ataxia Telangiectasia Mutated). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04656262 -
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
|
Phase 3 | |
Recruiting |
NCT03077178 -
Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over
|
N/A | |
Not yet recruiting |
NCT06110650 -
A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma
|
N/A | |
Terminated |
NCT03735758 -
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
|
Phase 4 | |
Not yet recruiting |
NCT03951571 -
Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06273852 -
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
|
Early Phase 1 | |
Enrolling by invitation |
NCT03134742 -
Radiation Effects on Bone
|
||
Not yet recruiting |
NCT06252727 -
Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)
|
Phase 1 | |
Recruiting |
NCT04617327 -
Pre-operative RadiothErapy for Soft Tissue SarcOmas
|
N/A | |
Active, not recruiting |
NCT03526679 -
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04008238 -
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
|
N/A | |
Recruiting |
NCT04095208 -
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
|
Phase 2 | |
Recruiting |
NCT04330456 -
Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy
|
N/A | |
Completed |
NCT03833037 -
Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
|
||
Completed |
NCT03056599 -
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
|
Phase 1 | |
Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
Withdrawn |
NCT03104335 -
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
|
Phase 2 |